Protagonist Therapeutics, Inc.
NASDAQ: PTGX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dinesh V. Patel
- Employees
- 124
- Headquarters
- Newark, United States
- IPO year
- 2016
- Market cap
- $7.3B
- Website
- https://www.protagonist-inc.com
Loading PTGX…
Loading profile data…Frequently asked questions about PTGX
What does Protagonist Therapeutics, Inc. (PTGX) do?
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimet...
Where does PTGX trade?
Protagonist Therapeutics, Inc. (PTGX) trades on the NASDAQ Global Market.
What sector is PTGX in?
Protagonist Therapeutics, Inc. (PTGX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Protagonist Therapeutics, Inc.?
Dinesh V. Patel is the chief executive officer of Protagonist Therapeutics, Inc. (PTGX).
Where is Protagonist Therapeutics, Inc. headquartered?
Protagonist Therapeutics, Inc. is headquartered in United States.
Does PTGX pay a dividend?
Protagonist Therapeutics, Inc. (PTGX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did PTGX go public?
Protagonist Therapeutics, Inc. (PTGX) completed its initial public offering in 2016.